Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 46,308

Document Document Title
WO/2014/120815
The invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: formula (I). The invention also provides pharmaceutically acceptable compositions comprising the com...  
WO/2014/117220
The present disclosure relates to proteins that bind to CD83 and uses thereof, for example, in therapy, prophylaxis, diagnosis, or prognosis.  
WO/2014/120538
Methods of treatment of multiple sclerosis (MS) with PPARγ agonists, and in particular with the compound of formula (I) known as INT131.  
WO/2014/115885
 The present invention provides a novel therapeutic agent for demyelinating disease which acts to suppress the demyelination of the neuroaxis. The present invention provides a therapeutic agent for demyelinating disease, the therapeuti...  
WO/2014/117089
A method of treating a pervasive development disorder in a subject includes administering to the subject an amount of an NMDAR antagonist effective to ameliorate biochemical and functional abnormalities in the subject associated with los...  
WO/2014/116652  
WO/2014/116015
The present invention provides a functional composition for preventing Alzheimer's disease, containing a heat-treatment salt heat treated at 800-1,200℃ as an active ingredient, and other pharmaceutically or cytologically acceptable ing...  
WO/2014/116666
The present disclosure provides methods and kits for treating and classifying individuals at risk of or suffering from a neurological dysfunction or disorder. In general, the individuals are treated and/or classified based on the presenc...  
WO/2014/115072
The invention relates to heterocyclic amide derivatives of formula (I), wherein R1, R2, R3, R4, R5, n, m, p and X are as defined in the description, their preparation and their use as pharmaceutically active compounds.  
WO/2014/114248
The present invention relates to novel 3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of disea...  
WO/2014/114532
The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the prese...  
WO/2014/116132
Mammalian central nervous system (CNS) neurons do not regenerate after injury due to the inhibitory environment formed by the glial scar, largely constituted by myelin debris. The use of biomaterials to bridge the lesion area and the cre...  
WO/2014/114186
The present invention belongs to the field of pharmaceutical techniques, and in particular relates to JNK inhibitors as shown by general formulae (I), (1a) or (1b), pharmaceutically acceptable salts or stereoisomers thereof, the preparat...  
WO/2014/114694
The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for e...  
WO/2014/114742
A compound of formula (I) in which the dotted lines indicate the presence of at least one double bond; n = 0 to 4; R3 and R4 are H, or when n = 1, R3 and R4 can also form together a double bond between the carbon atoms, and m = 0, 1 or 2...  
WO/2014/116739
Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurological dysfunction.  
WO/2014/113878
A method is disclosed to dissolve protein deposited in muscle. The method includes the step of administering an effective amount of an agent selected from the group consisting of fibrinolytics, proteolytics, photolytic and magnelytic age...  
WO/2014/115853
The propellane derivatives represented by general formula (I) or pharmaceutically-acceptable acid addition salts thereof, or hydrates or solvates of said propellane derivatives and acid addition salts are used as analgesics, antidepressa...  
WO/2014/115098
The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount ...  
WO/2014/117176
The present invention relates in some aspects to compositions (e.g., pharmaceutical, nutritional compositions, etc.), formulations, and food or beverage products comprising, consisting essentially of, or consisting of (a) β-alanine or a...  
WO/2014/114779
The present invention is directed to N-substituted-5-substituted phthalamic acids which of formula (A). The compounds are considered useful for the treatment of diseases treatment of a neurodegenerative disease, psychiatric disease, moto...  
WO/2014/115430
The present invention provides: a humanized anti-HMGB1 antibody that binds specifically to a sequence consisting of an eight-amino-acid residue (EEEDDDDE) at the C terminal of the HMGB1 protein, and that is effective in the treatment or ...  
WO/2014/113844
The present invention relates to the field of biomarkers and in particular to their utilisation in treatment. Embodiments of the invention have been particularly developed as biomarkers enabling optimisation of treatment regimes and as u...  
WO/2014/114032
A non-addictive analgesic sustained-release drug delivery system, comprising: (1) a narcotic analgesic drug having a concentration of 1 mg/ml-160 mg/ml, the drug being selected from a group consisting of: a local analgesic drug, and the ...  
WO/2014/114627
The invention relates to a pharmaceutical combination of 2-aminoethanesulfonic acid with a phannaceutical agent such as an antihypertensive agent and the use of 2-aminoethanesulfonic acid in a method to lower the bilirubin level in the b...  
WO/2014/114695
The present invention relates to novel pyrimidine derivatives of formula (I)[Formula should be entered here] as inhibitors of the enzyme phosphodiesterase 10 (PDE-10), pharmaceutical compositions comprising an effective amount of these c...  
WO/2014/113750
The invention comprises novel inhibitors of dipeptidyl peptidase IV (DPP-IV) with beta blocker activity, pharmaceutical compositions comprising therapeutically effective amounts of novel inhibitors of DPP-IV, and novel methods of treatin...  
WO/2014/111457
The present invention is concerned with novel substituted pyrido-piperazinone derivatives of Formula (I) wherein R1, R2, R3, R4, R5, L, Z and X have the meaning defined in the claims. The compounds according to the present invention are ...  
WO/2014/112676
The present invention relates to a massage oil for deep sleep in which a valerian oil, a lavender oil, and a chamomile roman oil are mixed. According to the present invention, the massage oil effectively treats insomnia and especially sh...  
WO/2014/111751
The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonists for the treatment, amelioration, prevention or delay of progression of narcolepsy, excessive daytime sleepiness, nocturnal sleep disruption and/o...  
WO/2014/111957
The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents wherein the drug or therapeutic agents contain at least one carboxylic acid group. The invention also relates to processes for the prep...  
WO/2014/113609
Stable indole-3-propionic acid salts of S-adenosyl-L-methionine, or a pharmaceutically acceptable salt thereof, are disclosed, as well as pharmaceutical compositions comprising the indole-3-propionic acid salts, methods of using the indo...  
WO/2014/112152
Provided is a medicine used as an external preparation for treatment of local symptoms of neuropathic disease, wherein gabapentine or pregabalin is contained in the form of an aqueous solution.  
WO/2014/113539
The present invention relates to the isolation of polypeptides derived from the Clostridium botulinum neurotoxin and the use thereof as treatment for neuronal injury such as spinal cord injury. Botulinum neurotoxin binds to neural cells ...  
WO/2014/111028
Disclosed in the present invention are a new genistein alkylamine compound (I) and pharmaceutically acceptable salts thereof, and the preparation method and use thereof in the preparation of drugs for the treatment and/or prevention of d...  
WO/2014/111496
The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. (I) In compounds of Formula I, the groups R1, R2, R3, R4, ...  
WO/2014/111004
Disclosed are a flavone alkylamine compound of formula (I), pharmaceutically acceptable salt and preparation method thereof, pharmaceutical composition, and uses thereof in the preparation of drugs for treating and/or preventing neurodeg...  
WO/2014/112492
[Problem] To provide novel compounds having agonist activity on dopamine D2 receptors. [Solution] Provided are compounds represented by general formula (I) (in the formula, R1 is a C1-6 alkyl or the like; R2 is a C1-6 alkyl, aralkyl, het...  
WO/2014/111356
The invention relates to the use of a compound of formula I wherein A1 is phenyl or a five or six membered hereroaryl group, containing 1, 2 or 3 heteroatoms, selected from N or S; R1 is hydrogen, lower alkyl, halogen, lower alkyl substi...  
WO/2014/113624
Amine chelates capable of antioxidant capacity and amyloid disaggregation are shown which may be useful in targeting metal-based oxidative stress in neurodegenerative disorders. Pyclen, a backbone commonly investigated for contrast agent...  
WO/2014/113359
The present invention provides an aqueous pharmaceutical composition comprising the fusion protein whose amino acid sequence is set forth as SEQ ID NO:1 and an aqueous solution comprising 40 to 60 mM sodium phosphate. The present inventi...  
WO/2014/111839
Disclosed is a compound of formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and m are as described herein, as a modulator of nicotinic acetylcholine receptors particularly α7 subtype, its tautomeric forms, its stereoisomers, its pharmace...  
WO/2014/112641
A nitric oxide (NO) concentration elevating agent containing glutathione or a salt thereof as an active ingredient, an NO concentration elevating agent containing glutathione or a salt thereof as an active ingredient for preventing or al...  
WO/2014/113822
Some embodiments comprise methods, systems, and compositions to promote, improve and/or increase neuronal differentiation, oligodendrocyte differentiation, or neurological outcome or function in a patient in need thereof. Some embodiment...  
WO/2014/112145
The present invention mainly addresses the problem of providing a radical curing agent for a disease associated with neuroaxonal dysfunction (for example, Alzheimer's disease, dementia, Parkinson's disease, spinal cord injury, brain cont...  
WO/2014/107771
Substituted indazole or imidazole derivatives of formula I as in vitro selective and reversible MAO-B inhibitors and for use in the prevention and treatment of meurodegenerative disorders such as Parkinson's disease, Alzheimer's disase a...  
WO/2014/110154
Disclosed herein are new oral pharmaceutical compositions of SAMDC inhibitors, polyamine analogs, and polyamine biosynthesis inhibitors, and their application for the treatment of conditions including demyelinating diseases, autoimmune d...  
WO/2014/108520
The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein:R1 is alkyl, Cl, F or Br; R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R...  
WO/2014/110090
In one embodiment, the invention provides a method of regenerating organs and tissues in a subject suffering from one or more organ or tissue manifestations of glucose supply side associated metabolic syndrome, the method comprising: (a)...  
WO/2014/110065
A dual H1 inverse agonist/5-HT2A receptor antagonist of the formula: [Formula I], its uses, and methods for its preparation are described.  

Matches 101 - 150 out of 46,308